Top 10 Breast Cancer Breakthroughs in 2024 - targetedonc.com
2024年12月23日 · In 2024, several significant advancements in breast oncology were covered by Targeted Oncology TM. Here are the top 10 developments from the year: FDA Approval of …
CAPOX Regimen Appears Noninferior to FOLFOX in Colorectal …
2023年10月8日 · The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and …
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
2024年10月8日 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma …
GLP-1 Agonists Poised to Impact Breast Cancer Care
2024年9月25日 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing …
The Targeted Pulse: Tune-In to Discover The Most Recent FDA …
2024年12月15日 · Zenocutuzumab Gains Gold With FDA Approval in NSCLC and Pancreatic Cancer. Zenocutuzumab (formerly MCLA-128) has received FDA approval for the treatment of …
TNBC Vaccine Shows Promising Safety, Immune Response in …
2024年11月22日 · An investigational breast cancer vaccine for triple-negative breast cancer (TNBC) showed encouraging results, with over 70% of patients exhibiting protocol-defined …
HT-6184 Advances to Second Stage of Phase 2 Trial in LR-MDS
2024年12月17日 · The second stage of a phase 2 trial exploring the first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor HT-6184 for the treatment of patients with lower-risk …
SEQUOIA Trial: Updates from ASH 2024 - targetedonc.com
2024年12月21日 · Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic lymphocytic leukemia and small lymphocytic …
T-DXd in ER+/HER2-Low Breast Cancer: Insights From DESTINY …
2024年12月11日 · Aditya Bardia, MD, MPH, FASCO, professor, department of medicine, division of hematology/oncology, director of translational research integration, UCLA Health Jonsson …
Dual Immunotherapy Clinically Active in Anaplastic Thyroid Cancer
2024年12月23日 · Dual immune checkpoint inhibition with nivolumab (Opdivo) and ipilimumab (Yervoy) shows promise for the treatment of anaplastic thyroid cancer (ATC), but offers limited …